Two-step nanoprecipitation for the production of protein-loaded PLGA nanospheres

Results in Pharma Sciences

Volumn 2, Issue 1, 2012, Pages 79-85

  Morales Cruz, Moraima ^a   Flores Fernández, Giselle M ^a   Morales Cruz, Myreisa ^a   Orellano, Elsie A ^a   Rodriguez Martinez, José A ^a   Ruiz, Mercedes ^a   Griebenow, Kai ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Nanoparticle; Nanoprecipitation; Pharmaceutical protein; Protein stability; Sustained release

Indexed keywords

CHYMOTRYPSIN A; CYTOCHROME C; GLYCOLIC ACID; LACTIC ACID; LYSOZYME; MICROSPHERE; NANOPARTICLE; NANOSPHERE; POLYGLACTIN;

APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EMULSION; ENDOCYTOSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOENCAPSULATION; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; THICKNESS;

EID: 84870485258     PISSN: None     EISSN: 22112863     Source Type: Journal    
DOI: 10.1016/j.rinphs.2012.11.001     Document Type: Article

References (43)

1. Brannon-Peppas L, Blanchette JO Nanoparticle and targeted systems for cancer therapy. Advanced Drug Delivery Reviews 2004, 56:1649-1659.
2. Singh R, Lillard JW Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology 2009, 86:215-223.
3. Alexis F, Pridgen E, Linda K, Molnar LK, Farokhzad OC Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmacology 2008, 5(4):505-515.
4. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, Wrasidlo W, Cheresh DA Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proceedings of the National Academy of Sciences USA 2008, 105(27):9343-9348.
5. Pathak P, Katiyar VK Multi-functional nanoparticles and their role in cancer drug delivery-a review. Journal of Nanotechnology 2007, 1-18.
6. Han G, Ghosh P, Rotello VM Functionalized gold nanoparticles for drug delivery. Nanomedicine 2007, 2(1):113-123.
7. Davis ME, Chen ZG, Shin DM Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews Drug Discovery 2008, 7:771-782.
8. Gelperina S, Kisich K, Iseman MD, Heifets L The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. American Journal of Respiratory and Critical Care Medicine 2005, 172(12):1487-1490.
9. Shive MS, Anderson JM Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews 1977, 28(1):5-24.
10. Pridgen EM, Langer R, Farokhzad OC Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine 2007, 2(5):669-680.
11. Langer R, David A, Tirrell DA Designing materials for biology and medicine. Nature 2004, 428:487-492.
12. Fessi H, Puisieux F, Devissaguet JPh, Ammoury N, Benita S Nanocapsule formation by interfacial polymer deposition following solvent displacement. International Journal of Pharmaceutics 1989, 55:R1-R4.
13. Bilati U, Allemann E, Doelker E Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. European Journal of Pharmaceutical Sciences 2005, 24(1):67-75.
14. Pérez C, Castellanos IJ, Costantino HR, Al-Azzam W, Griebenow K Recent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers. Journal of Pharmacy and Pharmacology 2002, 54:301-313.
15. Barichello JM, Morishita M, Takayama K, Nagai T Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Development and Industrial Pharmacy 1999, 25(4):471-476.
16. Bilati U, Allemann E, Doelker E. Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issues. AAPS PharmSciTec. 2005;6(4):E594-604.
17. Griebenow K, Klibanov AM Can conformational changes be responsible for solvent and excipient effects on the catalytic behavior of subtilisin Carlsberg in organic solvents?. Biotechnology and Bioengineering 1997, 53(4):351-362.
18. Xu K, Griebenow K, Klibanov AM Correlation between catalytic activity and secondary structure of subtilisin dissolved in organic solvents. Biotechnology and Bioengineering 1997, 56:485-491.
19. Giteau A, Venier-Julienne MC, Marchal S, Courthaudon JL, Sergent M, Montero-Menei C, Verdier JM, Benoit JP Reversible protein precipitation to ensure stability during encapsulation within PLGA microspheres. European Journal of Pharmaceutics and Biopharmaceutics 2008, 70:127-136.
20. Montalvo BL, Pacheco Y, Sosa BA, Vélez D, Sánchez G, Griebenow K Formation of spherical protein nanoparticles without impacting protein integrity. Nanotechnology 2008, 19:465103.
21. Griebenow K, Klibanov AM On protein denaturation in aqueous-organic but not in pure organic solvents. Journal of the American Chemical Society 1996, 118:11695-11700.
22. Griebenow K, Klibanov AM Can conformational changes be responsible for solvent and excipient effects on the catalytic behavior of subtilisin Carlsberg in organic solvents?. Biotechnology and Bioengineering 1997, 53:351-362.
23. Griebenow K, Vidal M, Baéz C, Santos AM, Barletta G Native-like enzyme properties are important for optimum activity in neat organic solvents. Journal of the American Chemical Society 2001, 123:5380-5381.
24. Santra S, Kaittanis C, Perez JM Cytochrome c encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy. Molecular Pharmacology 2010, 7(4):1209-1222.
25. Weber C, Coester C, Kreuter J, Langer K Desolvation process and surface characterisation of protein nanoparticles. International Journal of Pharmaceutics 2000, 194(1):91-102.
26. Perez C, De Jesus P, Griebenow K Preservation of lysozyme structure and function upon encapsulation and release from poly(lactic-co-glycolic) acid microspheres prepared by the water-in-oil-in-water method. International Journal of Pharmaceutics 2002, 248:193-206.
27. Castellanos IJ, Cruz G, Crespo R, Griebenow K Encapsulation-induced aggregation and loss in activity of γ-chymotrypsin and their prevention. Journal of Controlled Release 2002, 81:307-319.
28. Castellanos IJ, Griebenow K Improved α-chymotrypsin stability upon encapsulation in PLGA microspheres by solvent replacement. Pharmaceutical Research 2003, 20:1873-1880.
29. Peréz C, Griebenow K Improved activity and stability of lysozyme at the water/methylene chloride interface: enzyme unfolding and aggregation and its prevention by polyols. Journal of Pharmacy and Pharmacology 2001, 53:1217-1226.
30. Kim NH, Jeong MS, Choi SY, Kang JH Peroxidase activity of cytochrome c. Bulletin of the Korean Chemical Society 2004, 25:1889-1892.
31. Blanco MD, Alonso MJ Development and characterization of protein loaded poly (lactide-co-glycolide nanospheres. European Journal of Pharmaceutics and Biopharmaceutics 1997, 43:287-294.
32. Song CX, Labhasetwar V, Murphy H, Qu X, Humphrey WR, Shebuski RJ, Levy RJ Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. Journal of Controlled Release 1997, 43:197-212.
33. Chang MW, Stride E, Edirisinghe M. Controlling the thickness of hollow polymeric microspheres prepared by electrohydrodynamic atomization. Journal of the Royal Society Interface 2010, 7:S451-S460.
34. Castellanos IJ, Flores G, Griebenow K Effect of cyclodextrins on α- chymotrypsin stability and loading in PLGA microspheres upon s/o/w encapsulation. Journal of Pharmaceutical Sciences 2005, 95(4):849-858.
35. Castellanos IJ, Al-Azzam W, Griebenow K Effect of the covalent modification with poly(ethylene glycol) on α-chymotrypsin stability upon encapsulation in poly(lactic-co-glycolic) microspheres. Journal of Pharmaceutical Sciences 2005, 92:327-340.
36. Castellanos IJ, Crespo R, Griebenow K Poly(ethylene glycol) as stabilizer and emulsifying agent: a novel stabilization approach preventing aggregation and inactivation of proteins upon encapsulation in bioerodible polyester microspheres. Journal of Controlled Release 2003, 88:135-145.
37. Cho K, Wang X, Nie S, Chen Z, Shin DM Therapeutic nanoparticles for drug delivery in cancer. Clinical Cancer Research 2008, 5:1310-1316.
38. Danhier F, Feron O, Préat V To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release 2010, 148:135-146.
39. Valdez D., J -Y.Le Huérou, Gindre M., Urbach W., Waks M. Hydration and protein folding in water and in reverse micelles: compressibility and volume changes. Biophysical Journal 2001, 80:2751-2760.
40. Gref R, Quellec P, Sanchez A, Calvo P, Dellacherie E, Alonso MJ Development and characterization of Cyt-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. European Journal of Pharmaceutics and Biopharmaceutics 2001, 51:111-118.
41. Xu P, Gullotti E, Tong L, Highley CB, Errabelli DR, Hasan T, Cheng J-X, Kohane DS, Yeo Y Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Molecular Pharmacology 2009, 6(1):190-201.
42. Knubovets T, Osterhout JJ, Klibanov AM Structure of lysozyme dissolved in neat organic solvents as assessed by NMR and CD spectroscopies. Biotechnology and Bioengineering 1999, 63:242-248.
43. Jackson M, Mantsch HH Beware of proteins in DMSO. Biochimica et Biophysica Acta: Protein Structure and Molecular Enzymology 1991, 1078:231-235.